Target family: Chemokine receptors (type: gpcr)
Target: CCR4

Ligand: AZD1678 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD1678 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD1678 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD1678 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD2098 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD2098 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD2098 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: AZD2098 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
Published in: ACS Med Chem Lett

Ligand: CCL17 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.7 pIC50
Reference (Journal): Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.
Published in: J Biol Chem

Ligand: compound 31 [PMID: 31259550] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor Microenvironment.
Published in: J Med Chem

Ligand: compound 8ic [PMID: 19081254] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.
Published in: Bioorg Med Chem

Ligand: FLX475 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Patent): Chemokine receptor modulators and uses thereof

Ligand: GSK2239633A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 7.829999923706055 pIC50
Reference (Journal): Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Published in: J Med Chem

Ligand: mogamulizumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: yes
Approval source: PMDA (Japan, 2012), EMA & FDA (2018)
Primary target: yes
Median affinity:  -
Reference (Patent): Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens.

Ligand: mogamulizumab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: yes
Approval source: PMDA (Japan, 2012), EMA & FDA (2018)
Primary target: yes
Median affinity:  -
Reference (Journal): Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
Published in: Curr Opin Mol Ther

Ligand: [125I]CCL17 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: [125I]CCL27 (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: vMIP-III (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: zelnecirnon (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Patent): Chemokine receptor modulators and uses thereof